ANUH PHARMA 2020-21 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ANUH PHARMA 2020-21 Annual Report Analysis
Wed, 27 Oct

ANUH PHARMA has announced its results for the year ended March 2021. Let us have a look at the detailed performance review of the company during FY20-21.

ANUH PHARMA Income Statement Analysis

  • Operating income during the year rose 40.7% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 94.2% YoY during the fiscal. Operating profit margins witnessed a fall and down at 10.4% in FY21 as against 7.6% in FY20.
  • Depreciation charges increased by 114.4% and finance costs increased by 61.4% YoY, respectively.
  • Other income grew by 150.2% YoY.
  • Net profit for the year grew by 98.8% YoY.
  • Net profit margins during the year grew from 4.6% in FY20 to 6.4% in FY21.

ANUH PHARMA Income Statement 2020-21

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Net Sales Rs m 3,070 4,320 40.7%
Other income Rs m 42 105 150.2%
Total Revenues Rs m 3,112 4,425 42.2%
Gross profit Rs m 232 451 94.2%
Depreciation Rs m 70 151 114.4%
Interest Rs m 13 20 61.4%
Profit before tax Rs m 192 386 101.2%
Tax Rs m 49 101 108.6%
Profit after tax Rs m 143 284 98.8%
Gross profit margin % 7.6 10.4
Effective tax rate % 25.3 26.2
Net profit margin % 4.6 6.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



WATCH NOW: Top 3 Stocks for 2022 MEGA Summit... For free

ANUH PHARMA Balance Sheet Analysis

  • The company's current liabilities during FY21 down at Rs 1 billion as compared to Rs 2 billion in FY20, thereby witnessing an decrease of -14.3%.
  • Current assets rose 7% and stood at Rs 2 billion, while fixed assets fell 8% and stood at Rs 949 million in FY21.
  • Overall, the total assets and liabilities for FY21 stood at Rs 3 billion as against Rs 3 billion during FY20, thereby witnessing a growth of 2%.

ANUH PHARMA Balance Sheet as on March 2021

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Networth Rs m 1,622 1,906 17.5
 
Current Liabilities Rs m 1,627 1,395 -14.3
Long-term Debt Rs m 0 0 0.0
Total Liabilities Rs m 3,264 3,326 1.9
 
Current assets Rs m 2,230 2,377 6.6
Fixed Assets Rs m 1,034 949 -8.2
Total Assets Rs m 3,264 3,326 1.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



ANUH PHARMA Cash Flow Statement Analysis

  • ANUH PHARMA's cash flow from operating activities (CFO) during FY21 stood at Rs -187 million on a YoY basis.
  • Cash flow from investing activities (CFI) during FY21 stood at Rs 522 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY21 stood at Rs -331 million on a YoY basis.
  • Overall, net cash flows for the company during FY21 stood at Rs 4 million from the Rs -54 million net cash flows seen during FY20.

ANUH PHARMA Cash Flow Statement 2020-21

Particulars No. of months 12 12 % Change
Year Ending Mar-20 Mar-21
Cash Flow from Operating Activities Rs m 489 -187 -
Cash Flow from Investing Activities Rs m -765 522 -
Cash Flow from Financing Activities Rs m 222 -331 -
Net Cash Flow Rs m -54 4 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for ANUH PHARMA

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 5.7, an decline from the EPS of Rs 5.7 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 110.1, stands at 31.9 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 3.6 times, while the price to sales ratio stands at 1.6 times.
  • The company's price to cash flow (P/CF) ratio stood at 12.7 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Sales per share (Unadj.) Rs 122.5 86.2
TTM Earnings per share Rs 5.7 5.7
Diluted earnings per share Rs 2.9 5.7
Price to Cash Flow x 12.9 12.7
TTM P/E ratio x 15.9 31.9
Price / Book Value ratio x 2.1 3.6
Market Cap Rs m 2,759 5,517
Dividends per share (Unadj.) Rs 2.8 1.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for ANUH PHARMA

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.7x during FY21, from 1.4x during FY20. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 20.0x during FY21, from 16.2x during FY20. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 14.9% during FY21, from 8.8% during FY21. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 21.3% during FY21, from 12.6% during FY20. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 9.2% during FY21, from 4.8% during FY20. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Current ratio x 1.4 1.7
Debtors’ Days Days 964 903
Interest coverage x 16.2 20.0
Debt to equity ratio x 0.0 0.0
Return on assets % 4.8 9.2
Return on equity % 8.8 14.9
Return on capital employed % 12.6 21.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how ANUH PHARMA has performed over the last 5 years, please visit here.

ANUH PHARMA Share Price Performance

Over the last one year, ANUH PHARMA share price has moved down from Rs 156.3 to Rs 110.1, registering a loss of Rs 46.2 or around 29.6%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 25,357.3 (up 0.6%). Over the last one year it has moved up from 19,666.1 to 25,357.3, a gain of 5,691 points (up 28.9%).

Overall, the S&P BSE SENSEX is up 52.3% over the year.

(To know more, check out historical annual results for ANUH PHARMA and quarterly results for ANUH PHARMA)

Equitymaster requests your view! Post a comment on "ANUH PHARMA 2020-21 Annual Report Analysis". Click here!

  

Related Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

India's Best Semiconductor Stocks(Views On News)

Jan 7, 2022

Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Looking for Consistent Compounding Stocks? Here's a Watchlist for You(Views On News)

Jan 6, 2022

These companies have generated mind boggling returns for investors over the years.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ANUH PHARMA

  • Track your investment in ANUH PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ANUH PHARMA - RELISH PHARMA COMPARISON

COMPARE ANUH PHARMA WITH

MARKET STATS